Endocrine Disruption Screening Market
Number of pages: 100 | Report Format: PDF | Published date: March 13, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
Market Size Value in 2022 |
US$ 142.3 million |
|
Revenue Forecast in 2031 |
US$ 190.6 million |
|
CAGR |
3.3% |
|
Base Year for Estimation |
2022 |
|
Forecast Period |
2023-2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Assay Type, Method, End-user, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global endocrine disruption screening market was valued at US$ 142.3 million in 2022 and is expected to register a revenue CAGR of 3.3% to reach US$ 190.6 million by 2031.
Endocrine Disruption Screening Market Fundamentals
The endocrine system, which regulates the hormones in the body, may be mimicked or interfered with by several natural and manufactured chemicals. These substances, often termed endocrine disruptors, are responsible for developing reproductive, brain, immunological, and other issues. Several common household items contain hormone disruptors, such as plastic bottles and containers, the linings of metal food cans, detergents, flame retardants, food, toys, cosmetics, and pesticides. Since the middle of the 1990s, there has been an increase in knowledge and concerns about the health implications due to exposure to chemicals that could potentially disrupt the endocrine system of humans and wildlife. Many substances have been found to interact with animals’ endocrine systems in lab experiments, and there are numerous reports of endocrine disruption in wild animals. Since a few years ago, the scientific community and the general public have widely addressed the potential impact of disruptive endocrine substances on the environment. These negative effects include the growth of cancerous tumors in the breast, prostate, thyroid, and other cancers; problems with sexual development, such as the masculinization or feminization of males or females; and other developmental disorders, such as attention deficit disorder, learning disabilities, cognitive and brain development issues, along with body deformation. The endocrine system is disrupted by chemicals primarily through three methods. Firstly, the endocrine system is disrupted by mimicking or amplifying the activity of endogenous hormones. Then the endocrine system is disrupted by blocking a hormone receptor to stop an endogenous hormone from acting and by interfering with an endogenous hormone’s synthesis, transport, or metabolism to disturb the endocrine system.
[567567]
Endocrine Disruption Screening Market Dynamics
National and international governments are establishing testing programs and strategies to evaluate the safety of presently used chemicals concerning their potential to interact with the endocrine systems of people and wildlife and negatively affect reproduction, growth, and development. Several nations, including the U.S., Japan, and Europe, have established testing methodologies and regulatory frameworks to analyze the hazards posed by chemicals that have endocrine-disruptive qualities. However, while significant efforts have been made over the past 20 years to assess the safety of chemicals, there have been no similar efforts for endocrine disruption chemicals to unify and mutually accept testing methodologies and decision-making standards. Many current environmental regulations, including the U.S. Clean Water Act and the European Water Framework Directive (WFD), do not specifically test for endocrine disruption screening. As a result, it is unlikely that these regulations will adequately address exposure to these chemicals, given the particular criteria and endpoints needed to evaluate a sample’s endocrine potential. Therefore, the lack of proper regulations fuels the demand for endocrine disruption screening methods.
One of the major global environmental concerns is the significant increase in pollutant discharges into the environment due to the rapid growth of industrial and agricultural activities. Several synthetic chemicals, classified as possible environmental endocrine-disrupting chemicals (EDCs), impact cattle, wildlife, and human health. The endocrine system is disrupted by interfering with an endogenous hormone’s synthesis, transport, or metabolism. Even though various epidemiological and experimental investigations have linked environmental EDCs with altered human health, there has been a rise in public awareness of the risks associated with human exposure to these substances. EDCs are linked to harmful effects on both male and female reproductive health; they also raise the risk of hormone-sensitive malignancies and cause diabetes, obesity, metabolic disorders, and thyroid imbalance. Many EDCs have their main sources in sewage effluents, which eventually reach huge water bodies and may taint the drinking water supply.
Water storage materials, including various plastics, allow endocrine disruption chemicals to seep into drinking water. Household wastewater contaminated with metals, pesticides, pharmaceutical chemicals, and additives from personal care products also affects endocrine function. These EDCs work through several receptors using known and unidentified methods, including epigenetic alteration. They differ from conventional toxins in several respects, including trans-generational effects, non-monotonic dose, and low-dose action. Therefore, increased industrialization and pollution necessitate the screening of endocrine disruption, which drives the revenue growth of the global market.
However, the lack of awareness and the high cost of the screening program with complex testing procedures hinder the development of the global endocrine disruption screening market growth.
Endocrine Disruption Screening Market Ecosystem
The global endocrine disruption screening market is analyzed from four perspectives: assay type, method, end-user, and region.
Endocrine Disruption Screening Market by Assay Type
[785675]
Based on the assay type, the global endocrine disruption screening market is segmented into in vivo and in vitro assays.
The in vitro assay segment accounted for the largest revenue share of the global endocrine disruption screening market in 2022. High throughput screening assays can be used to determine how chemicals affect the molecular beginnings of biological or toxicological processes. In vitro high throughput screening experiments combining competitive ligand binding, reporter gene activation, and enzyme inhibition can be utilized to define the chemical potential for endocrine disruption. Investigating correlations with the guideline endocrine disruption screening T1S assay outcomes allows for a quantitative evaluation of these chemical characterizations. Also, the in vitro assay possesses high sensitivity for single molecule detection, fast automation, sample reduction in the case of microtiter plate assay, and the capacity to identify weak background signals, which are the main benefits. It mostly leverages automation and huge dataset processing to quickly test the biological or biochemical activity of numerous small molecule libraries. In medicinal chemistry, ADMET/PK, pharmacology, chemical biology, target identification, target validation, and mechanism of action, it is regarded as a starting point for several drug development projects for screening.
Endocrine Disruption Screening Market by Method
Based on the method, the global endocrine disruption screening market is segmented into estrogen receptor transactivation, androgen receptor transactivation, androgen receptor modulation, estrogen receptor-alpha binding, steroidogenesis, aromatase assay, and others.
The estrogen receptor transactivation segment accounted for the largest revenue share of the global endocrine disruption screening market in 2022. The in vitro assays examined several estrogen receptor (ER) signaling endpoints, including binding, agonist, antagonist, and cell growth responses. An ER Interaction Score was developed using the in vitro experimental data. In the creation of the most effective treatments for the prevention and treatment of breast cancer, for the replacement of menopausal hormones, and for the control of fertility, estrogens exhibit an intriguing tissue-selective activity that is of enormous biological value. Selective estrogen receptor modulators, a class of drugs that act through the ER, can exhibit striking variances in activity in the various estrogen target tissues, acting as agonists in some tissues but antagonists in others. Understanding these tissue-selective activities of estrogens is aided by recent discoveries that reveal the tripartite character of their biochemical and molecular functions.
Endocrine Disruption Screening Market by End-user
Based on the end-user, the global endocrine disruption screening market is segmented into pharmaceutical and biopharmaceutical companies, cosmetics and household product companies, the food industry, and the chemical industry.
The pharmaceutical and biopharmaceutical companies segment accounted for the largest revenue share of the global endocrine disruption screening market in 2022. Due to the expanding usage in drug development and numerous other pharmaceutical applications, safety concern is the most important aspect of the production prospects. The need for endocrine disruption screening systems in the pharmaceutical manufacturing unit to maintain quality is projected to increase demand in the coming years. The pharmaceutical business recognizes them as essential excipients for creating most dosage forms. Growing health concerns and increasing awareness of the importance of medications are projected to fuel the demand for the best-quality pharmaceuticals, which will present profitable growth prospects for endocrine disruption screening in the near future.
Endocrine Disruption Screening Market by Region
Based on the region, the global endocrine disruption screening market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
North America accounted for the largest revenue share of the global endocrine disruption screening market in 2022. Due to the presence of prominent players, North America currently dominates the market for endocrine disruption screening. Additionally, the rise is anticipated to be supported by North America’s simplified repayment requirements and an increase in the occurrence of hormonal diseases. A well-developed healthcare infrastructure, the presence of industry titans, recently launched cutting-edge instruments, and payment coverage are contributing to the region’s high demand for sophisticated healthcare services. The ongoing development of endocrine disruption screening programs is a major factor boosting market expansion.
Endocrine Disruption Screening Market Competitive Landscape
Endocrine disruption screening has a moderately competitive global market due to new product launches, mergers, and acquisitions. The introduction of novel therapeutics, obtaining approval for those products, and participating in other activities, such as awareness programs, are some key development strategies that many organizations emphasize. Additionally, the market classified partnerships, acquisitions, and other collaborations as improved growth strategies. Given the rising global market demand for endocrine disruption screening, these steps have increased the likelihood of having profitable growth prospects in the future.
The prominent participants in the global market include:
Endocrine Disruption Screening Market Strategic Developments
Endocrine disruption screening is the selection process of the chemical substances responsible for endocrine disruption in humans and animals.
The increased prevalence of endocrine disruption is the most important factor propelling the revenue growth of the endocrine disruption screening market.
High cost and lack of awareness about endocrine disruption screening are potentially restricting the revenue growth of the global market.
Key companies operating the global endocrine disruption screening market are Creative Bioarray, Xenometrix AG, Charles River, Eurofins Scientific, and Smithers.
The global endocrine disruption screening market is expected to grow at a revenue CAGR of 3.3% during the forecast period from 2023 to 2031.
*Insights on financial performance are subject to the availability of information in the public domain